SCHEMBL3703717

SCHEMBL3703717

Cc1n[nH]c2cc(Nc3nc(N)c4oc(C5CC5)cc4n3)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.39
▸ DAPK3 O43293 1/20 0.39
▸ STK16 O75716 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ RET P07949 1/20 0.39
▸ LTK P29376 1/20 0.39
▸ TTK P33981 1/20 0.39
▸ GRK5 P34947 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ SYK P43405 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ CSNK1A1 P48729 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ TNK2 Q07912 1/20 0.39
▸ MAP4K2 Q12851 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3703992 0.82 SYK (0.44) JAK2DAPK3MAP4K4PAK4ABL1
SCHEMBL3708736 0.81 NPC1 (0.34) ULK1KMT2ANPC1RAB9ATAAR1
SCHEMBL3703721 0.80 JAK2 (0.36) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL1709922 0.71 SYK (0.74) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL1709788 0.70 SYK (0.49) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL3704019 0.70 SYK (0.69) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL1709830 0.70 SYK (0.52) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL3703842 0.70 SYK (0.68) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL3703840 0.70 SYK (0.68) JAK2DAPK3STK16MAP4K4PAK4
SCHEMBL1709861 0.69 SYK (0.64) JAK2DAPK3STK16MAP4K4PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 JAK2 218/4885DAPK3 149/4885STK16 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback